MedTrace Logo

U-LABA/ICS Effects on Exercise Performance, Vilanterol

NCT06066606 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-04-10

No results posted yet for this study

Summary

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate

Conditions

  • Exercise Performance

Interventions

DRUG

Vilanterol and Fluticasone Furoate (low dose)

Participants are administered 25 µg of vilanterol + fluticasone furoate

DRUG

Vilanterol and Fluticasone Furoate (high dose)

Participants are administered 100 µg of vilanterol + fluticasone furoate

DRUG

Placebo

Participants are administered placebo

Sponsors & Collaborators

  • Morten Hostrup, PhD

    lead OTHER

Principal Investigators

  • Morten Hostrup, PhD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2026-07-15
Completion
2026-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06066606 on ClinicalTrials.gov